… trial with three stages that we intend to implement, to increase the effective dose to non–small-cell
lung … Since the object of the present dose-per-fraction escalation trial is to establish …

… planning results of these complex dose-escalation treatment plans. For the first 20 patients
included in the trial, we have evaluated the actual delivered treatment plans of the trial. The …

… to the selection of the safest and most promising schedules for dose-escalation trials, using
both conventional technology and the latest technical advances in lung cancer radiotherapy. …

… a randomised controlled trial of chemoradiotherapy for patients with stage III non-small-cell
lung cancer. … for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. …

… Trial design In our dose escalation trial, the OTT was restricted to 6 weeks and a fixed fraction
size of … plan, the dose in the lung was corrected for the effect of dose per fraction. The local …

… We also hypothesized that an increase in the dose … I dose escalation trial at the University
of Michigan in 1992 with the primary objective of establishing the maximum-tolerated dose (…

… –small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with …
heart dose in patients treated at our institution on several prospective dose-escalation trials. …

… dose escalation trial that started in our institute in October 1998 it was decided to keep the
overall treatment time fixed to 6 weeks. Since the dose … to report on the trial design and clinical …

… trial (NCT01629498). Major differences with our trial were that we did not escalate the dose
to the lymph nodes, consolidation chemotherapy was not allowed and the maximum dose to …

… to establish the maximum tolerated dose. The trial was initially designed to dose escalate by
increasing the … Because doses of 90.3 Gy on RTOG 9311 took over 9 weeks to deliver, this …